Christine A. Shaw

Christine A. Shaw

Auto-generated profile, based on publicly available information

Christine A. Shaw

Moderna, Inc

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2020 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Closed access
AAAntonios O. Aliprantis
Antonios O. Aliprantis
CSChristine A. Shaw
Christine A. Shaw
PGPaul Robert Griffin
Paul Robert Griffin
NFNicholas Farinola
Nicholas Farinola
RRRadha A. Railkar
Radha A. Railkar
LPLori Panther
Lori Panther
Respiratory Syncytial Virus (RSV) causes lower respiratory tract infections that can be severe and sometimes fatal. The risk for severe RSV infection is highest in infants and older adults. A safe and effective RSV vaccine for older adults represents a serious unmet medical need due to higher morbidity and mortality in this age group. In this randomized, partially double-blind, placebo-controlled, phase 1 dose-escalation study, we evaluated the safety, tolerability and immunogenicity of an investigational messenger ribonucleic acid (mRNA) vaccine encoding the RSV fusion protein (F) stabilized in the prefusion conformation. The study was conducted in healthy younger adults (ages ≥18 and ≤49 years) and healthy older adults (ages ≥60 and ≤79 years). Participants received mRNA-1777 (V171) or placebo as a single intramuscular dose. For each dose level, three sentinel participants were administered open-label mRNA-1777 (V171). Seventy-two younger adults were randomized and administered 25, 100, or 200 µg mRNA-1777 (V171) or placebo, and 107 older adults were randomized and administered 25, 100, 200 or 300 µg mRNA-1777 (V171) or placebo. Primary objectives were safety and tolerability and secondary objectives included humoral and cell-mediated immunogenicity. All dose levels of mRNA-1777 (V171) were generally well tolerated and no serious adverse events related to the vaccine were reported. Immunization with mRNA-1777 (V171) elicited a humoral immune response as measured by increases in RSV neutralizing antibody titers, serum antibody titers to RSV prefusion F protein, D25 competing antibody titers to RSV prefusion F protein, and cell-mediated immune responses to RSV-F peptides.

18 May 2023 in Vaccine
Verified
Journal Article
Closed access
CSChristine A. Shaw
Christine A. Shaw
AAAllison August
Allison August
SBStephan Bart
Stephan Bart
PBPeta-Gay Jackson Booth
Peta-Gay Jackson Booth
CKConor Knightly
Conor Knightly
LPLori Panther
Lori Panther

13 May 2024 in Pediatrics
Verified
Journal Article
Open access
PDF file
SGSabine Schnyder Ghamloush
Sabine Schnyder Ghamloush
BEBrandon Essink
Brandon Essink
BHBo Hu
Bo Hu
SKShiva Kalidindi
Shiva Kalidindi
LMLouie Morsy
Louie Morsy
CSChristine A. Shaw
Christine A. Shaw
OBJECTIVES: Human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3) are common respiratory illnesses in children. The safety and immunogenicity of an investigational mRNA-based vaccine, mRNA-1653, encoding membrane-anchored fusion proteins of hMPV and PIV3, was evaluated in hMPV/PIV3-seropositive children. METHODS: In this phase 1b randomized, observer-blind, placebo-controlled, dose-ranging study, hMPV/PIV3-seropositive children were enrolled sequentially into 2 dose levels of mRNA-1653 administered 2 months apart; children aged 12 to 36 months were randomized (1:1) to receive 10-μg of mRNA-1653 or placebo and children aged 12 to 59 months were randomized (3:1) to receive 30-μg of mRNA-1653 or placebo. RESULTS: Overall, 27 participants aged 18 to 55 months were randomized; 15 participants received 10-μg of mRNA-1653 (n = 8) or placebo (n = 7), whereas 12 participants received 30-μg of mRNA-1653 (n = 9) or placebo (n = 3). mRNA-1653 was well-tolerated at both dose levels. The only reported solicited local adverse reaction was tenderness at injection site; solicited systemic adverse reactions included grade 1 or 2 chills, irritability, loss of appetite, and sleepiness. A single 10-μg or 30-μg mRNA-1653 injection increased hMPV and PIV3 neutralizing antibody titers (geometric mean fold-rise ratio over baseline: hMPV-A = 2.9–6.1; hMPV-B = 6.2–13.2; PIV3 = 2.8–3.0) and preF and postF binding antibody concentrations (geometric mean fold-rise ratio: hMPV preF = 5.3–6.1; postF = 4.6–6.5 and PIV3 preF = 13.9–14.2; postF = 11.0–12.1); a second injection did not further increase antibody levels in these seropositive children. Binding antibody responses were generally preF biased. CONCLUSIONS: mRNA-1653 was well-tolerated and boosted hMPV and PIV3 antibody levels in seropositive children aged 12 to 59 months, supporting the continued development of mRNA-1653 or its components for the prevention of hMPV and PIV3.

31 January 2024 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
CSChristine A Shaw
Christine A Shaw
RMRuna Mithani
Runa Mithani
AKArchana Kapoor
Archana Kapoor
RDRakesh Dhar
Rakesh Dhar
LWLauren Wilson
Lauren Wilson
GCGrace L Chen
Grace L Chen
Background: Respiratory syncytial virus (RSV) presents a global health concern. A lipid nanoparticle–encapsulated mRNA-based RSV vaccine (mRNA-1345) that encodes the membrane-anchored RSV prefusion–stabilized F glycoprotein is under clinical investigation. Methods: This phase 1 dose escalation study was based on a randomized, observer-blind, placebo-controlled design, and it assessed the safety and immunogenicity of mRNA-1345 in healthy adults aged 18 to 49 years. Participants were randomized to receive 1 dose of mRNA-1345 (50, 100, or 200 µg) or placebo or 3 doses of mRNA-1345 (100 µg) or placebo 56 days apart. Results: mRNA-1345 was well tolerated at all dose levels. The most common solicited adverse reactions were pain, headache, fatigue, myalgia, or chills, which were all generally mild to moderate. At 1 month postinjection, a single injection of mRNA-1345 boosted RSV neutralizing antibody titers (geometric mean fold rise: RSV-A, 20.0–23.5; RSV-B, 11.7–16.0) and RSV prefusion binding antibody concentrations (geometric mean fold rise, 16.1–21.8), with no apparent dose response. Antibody levels remained above baseline through 6 months. Sequential doses of 100 µg were well tolerated but did not further boost antibody levels. Conclusions: A single mRNA-1345 injection demonstrated an acceptable safety profile in younger adults and induced a durable neutralizing antibody response, supporting its continued development. Clinical Trials Registration: ClinicalTrials.gov NCT04528719.

29 September 2023 in Vaccine
Verified
Journal Article
Closed access
JNJesse Nussbaum
Jesse Nussbaum
XCXin Cao
Xin Cao
RRRadha A. Railkar
Radha A. Railkar
JSJeffrey R. Sachs
Jeffrey R. Sachs
DSDaniel S. Spellman
Daniel S. Spellman
AEAmy S. Espeseth
Amy S. Espeseth

18 March 2025 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
ASAmanda K. Rudman Spergel
Amanda K. Rudman Spergel
JAJintanat Ananworanich
Jintanat Ananworanich
RGRuiting Guo
Ruiting Guo
WDWeiping Deng
Weiping Deng
LCLizbeth Carmona
Lizbeth Carmona
CSChristine A. Shaw
Christine A. Shaw